Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

New technologies in benign prostatic hyperplasia management

Roberts, William W.

doi: 10.1097/MOU.0000000000000277

Purpose of review Surgical debulking of the adenoma/transition zone has been the fundamental principle which underpins transurethral resection of the prostate – still acknowledged to be the gold-standard therapy for benign prostatic hyperplasia (BPH). However, there has been a recent resurgence in development of new BPH technologies driven by enhanced understanding of prostate pathophysiology, development of new ablative technologies, and the need for less morbid alternatives as the mean age and complexity of the treatment population continues to increase. The objective of this review is to highlight new BPH technologies and review their available clinical data with specific emphasis on unique features of the technology, procedural effectiveness and safety, and potential impact on current treatment paradigms.

Recent findings New technologies have emerged that alter the shape of the prostate to decrease urinary obstruction and enhance delivery of a lethal thermal dose by steam injection into the transition zone of the prostate. Energy can be delivered to the prostate via a beam of high-pressure saline or focused acoustic energy to mechanically disintegrate prostate tissue. Methods of cell death are being targeted with selectivity by the arterial supply with embolization and specific to prostate cells via injectable biological therapies.

Summary A number of new technologies are at various stages of development and improve on the transurethral resection of the prostate paradigm by moving closer to the ideal BPH therapy which is definitive, can be performed in minutes, in the office setting, with only local anesthesia and oral sedation.

Department of Urology and Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA

Correspondence to William W. Roberts, MD, University of Michigan, Ann Arbor, MI, USA. E-mail:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.